Heterogenous antibody and T‐cell responses to SARS‐CoV‐2 mRNA vaccines among immunocompromised young people

Baseline characteristics (Table 1, Figure 1A) were comparable between controls and the immunocompromised cohort, and disease groups were homogenous in terms of age and dose interval (p > .05) which have been reported to affect antibody titres. TABLE 1 Baseline characteristics, immunosuppressive m...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational medicine 2023-01, Vol.13 (1), p.e1183-n/a
Main Authors: Lu, Liangjian, Chan, Chang Yien, Chan‐Ng, Pauline P. L., Than, Mya, Tan, Pamela S. Y., Lim, Lee Kean, Teo, Sharon, Lau, Perry YW, Ng, Kar Hui, Ang, Elizabeth Y., Karthik, Sivaramakrishnan Venkatesh, Aw, Marion M., Tambyah, Paul A., Yap, Hui Kim, Lee, Bee Wah
Format: Article
Language:English
Subjects:
Adolescent
Antibodies
Arthritis
Biological products
Clinical medicine
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
Immunization
Inflammatory bowel disease
Kidney diseases
Kidney transplants
Letter to the Editor
Liver transplants
Lupus
Metabolites
mRNA vaccines
SARS-CoV-2 - genetics
Severe acute respiratory syndrome coronavirus 2
Steroids
T-Lymphocytes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Baseline characteristics (Table 1, Figure 1A) were comparable between controls and the immunocompromised cohort, and disease groups were homogenous in terms of age and dose interval (p > .05) which have been reported to affect antibody titres. TABLE 1 Baseline characteristics, immunosuppressive medication use, humoral and cellular vaccine responses in controls and immunocompromised young people Controls All immunocompromised IBD LTX KTX INS ESKD IGA JIA SLE UVI Others N 20 93 12 8 12 12 11 7 8 12 4 7 Baseline characteristicsa Age (years) 17.10 ± .66 17.58 ± .35 16.71 ± .89 17.28 ± 1.35 18.55 ± 1.03 17.43 ± .99 17.82 ± 1.12 18.88 ± 1.51 15.72 ± .9 18.50 ± .93 16.91 ± 1.43 17.29 ± 1.29 Female 7/20 (35) 47/93 (51) 8/12 (67) 5/8 (63) 6/12 (50) 4/12 (33) 1/11 (9) 5/7 (71) 3/8 (38) 11/12 (92) 2/4 (50) 2/7 (29) Pfizer 18/20 (90) 91/93 (98) 11/12 (92) 7/8 (89) 12/12 (100) 12/12 (100) 11/11 (100) 7/7 (100) 8/8 (100) 12/12 (100) 4/4 (100) 7/7 (100) Days between doses 1 and 2 31.70 ± 1.75 35.28 ± .93 32.67 ± 1.51 41.63 ± 4.30 39.33 ± 1.48 33.25 ± 2.07 41.09 ± 2.00 30.71 ± 4.3 38.63 ± 3.22 27.33 ± 1.17 32.50 ± 4.33 35.86 ± 4.69 Days after dose 2 38.75 ± 3.22 39.42 ± 1.36 40.92 ± 3.69 46.13 ± 3.36 37.67 ± 3.19 36.08 ± 3.38 38.82 ± 4.12 34.86 ± 3.53 37.63 ± 5.92 38.00 ± 3.75 42.50 ± 8.26 46.14 ± 7.40 Immunosuppressive medications Steroids 0/20 (0) 26/93 (28)** 0/12 (0) 2/8 (25) 12/12 (100) 1/12 (8) 0/11 (0) 4/7 (58) 0/8 (0) 4/12 (33) 0/4 (0) 3/7 (43) Anti-metabolites 0/20 (0) 64/93 (69)*** 11/12 (92) 3/8 (38) 10/12 (83) 11/12 (92) 0/11 (0) 7/7 (100) 4/8 (50) 12/12 (100) 2/4 (50) 4/7 (57) Calcineurin inhibitors 0/20 (0) 28/93 (30)** 0/12 (0) 7/8 (88) 12/12 (100) 5/12 (42) 0/11 (0) 1/7 (14) 0/8 (0) 0/12 (0) 0/4 (0) 3/7 (43) Biologics 0/20 (0) 16/93 (17) 4/12 (33) 0/8 (0) 0/12 (0) 0/12 (0) 0/11 (0) 0/7 (0) 6/8 (75) 0/12 (0) 3/4 (75) 3/7 (43) Humoral response to vaccination Anti-S > 250 U/ml 20/20 (100) 68/93 (73)** 10/12 (83) 8/8 (100) 6/12 (50) 5/12 (42) 11/11 (100) 2/7 (29) 7/8 (88) 8/12 (67) 4/4 (100) 7/7 (100) Anti-S > 100 U/ml 20/20 (100) 74/93 (80)* 12/12 (100) 8/8 (100) 9/12 (75) 5/12 (42) 11/11 (100) 2/7 (29) 7/8 (88) 9/12 (75) 4/4 (100) 7/7 (100) Anti-S > .8 U/ml 20/20 (100) 86/93 (92) 12/12 (100) 8/8 (100) 10/12 (83) 10/12 (83) 11/11 (100) 5/7 (71) 8/8 (100) 11/12 (92) 4/4 (100) 7/7 (100) Cellular response to vaccination Pan-T-cell IFNγ response (IU/ml) 1.75 (1.43–2.12) .71 (.59–.87)* .55 (.29–1.06) .45 (.17–1.24) .17 (.09–.33) .53 (.34–.82) 1.54 (.99–2.38) .75 (
ISSN:2001-1326
2001-1326
DOI:10.1002/ctm2.1183